{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CT+chest%2C+abdomen%2C+and+pelvis", "query": { "intervention": "CT chest, abdomen, and pelvis" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 48, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CT+chest%2C+abdomen%2C+and+pelvis&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-05T10:26:17.603Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05053659", "title": "Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Non Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Loncastuximab tesirine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Paolo Caimi, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2022-06-20", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-10-05T10:26:17.603Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05053659" }, { "nct_id": "NCT05825066", "title": "Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreas Adenocarcinoma", "Borderline Resectable Pancreatic Adenocarcinoma", "Locally Advanced Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Radiological Assessments", "type": "OTHER" }, { "name": "mFOLFIRINOX", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2023-08-01", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-05T10:26:17.603Z", "location_count": 2, "location_summary": "Charlotte, North Carolina • Winston-Salem, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05825066" }, { "nct_id": "NCT01485731", "title": "Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "Nelfinavir", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pelvic External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Brachytherapy", "type": "RADIATION" }, { "name": "Pharmacokinetic Sampling", "type": "PROCEDURE" }, { "name": "Cervical Biopsy", "type": "PROCEDURE" }, { "name": "Pelvic Examination", "type": "PROCEDURE" }, { "name": "Pap Smear", "type": "PROCEDURE" }, { "name": "Audiogram", "type": "PROCEDURE" }, { "name": "Proctoscopy", "type": "PROCEDURE" }, { "name": "Cytoscopy", "type": "PROCEDURE" }, { "name": "Renal Ultrasound", "type": "PROCEDURE" }, { "name": "CT Scan", "type": "PROCEDURE" }, { "name": "Whole Body PET/CT Scan", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 8, "start_date": "2012-01", "completion_date": "2015-02", "has_results": false, "last_update_posted_date": "2015-06-03", "last_synced_at": "2026-10-05T10:26:17.603Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01485731" }, { "nct_id": "NCT00001849", "title": "New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cushing Syndrome", "Endocrine Disease" ], "interventions": [ { "name": "Pentetreotide", "type": "DRUG" }, { "name": "18F-DOPA", "type": "DRUG" }, { "name": "CT scan", "type": "DEVICE" }, { "name": "MRI", "type": "DEVICE" }, { "name": "18-FDG", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 95, "start_date": "1999-05-20", "completion_date": "2019-04-26", "has_results": true, "last_update_posted_date": "2021-04-14", "last_synced_at": "2026-10-05T10:26:17.603Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001849" }, { "nct_id": "NCT05185947", "title": "Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gynecologic Cancer", "Gynecologic Neoplasms", "Peritoneal Carcinomatosis", "Peritoneal Neoplasms", "Ovarian Cancer", "Ovarian Neoplasms", "Colorectal Cancer", "Colorectal Neoplasms", "Appendiceal Cancer", "Appendiceal Neoplasms", "Cholangiocarcinoma", "Breast Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nilotinib", "type": "DRUG" }, { "name": "ECG", "type": "DIAGNOSTIC_TEST" }, { "name": "CT Scan CAP", "type": "DIAGNOSTIC_TEST" }, { "name": "Laparoscopy", "type": "PROCEDURE" }, { "name": "Peritoneal biopsies + ascites washings", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2022-10-13", "completion_date": "2025-01-27", "has_results": true, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-05T10:26:17.603Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05185947" }, { "nct_id": "NCT04538378", "title": "Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "EGFR-Mutated Non-Small-Cell Lung Carcinoma", "Small Cell/Neuroendocrine" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "Tumor biopsy", "type": "PROCEDURE" }, { "name": "CT chest, abdomen and pelvis", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI chest, abdomen and pelvis", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2021-07-07", "completion_date": "2024-02-27", "has_results": true, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-05T10:26:17.603Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04538378" }, { "nct_id": "NCT03092518", "title": "Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma", "Esophagogastric Junction", "Gastric Cancer" ], "interventions": [ { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Mitomycin C", "type": "DRUG" }, { "name": "Sodium Thiosulfate", "type": "DRUG" }, { "name": "Tumor Biopsy", "type": "PROCEDURE" }, { "name": "CT C/A/P", "type": "DIAGNOSTIC_TEST" }, { "name": "PET-CT", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "PROCEDURE", "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2017-06-05", "completion_date": "2024-07-24", "has_results": true, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-10-05T10:26:17.603Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03092518" }, { "nct_id": "NCT05507541", "title": "TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent ALK Positive Large B-Cell Lymphoma", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation", "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Grade 3b Follicular Lymphoma", "Recurrent High Grade B-Cell Lymphoma", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Intravascular Large B-Cell Lymphoma", "Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Refractory ALK Positive Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation", "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory Grade 3b Follicular Lymphoma", "Refractory High Grade B-Cell Lymphoma", "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified", "Refractory Intravascular Large B-Cell Lymphoma", "Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "Refractory Primary Mediastinal Large B-Cell Lymphoma", "Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Recurrent Gray Zone Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ontorpacept", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Maplirpacept", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2023-04-19", "completion_date": "2027-07-30", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-10-05T10:26:17.603Z", "location_count": 2, "location_summary": "Iowa City, Iowa • Rochester, Minnesota", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05507541" }, { "nct_id": "NCT05286827", "title": "Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Acinar Cell Carcinoma" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "ECG", "type": "DIAGNOSTIC_TEST" }, { "name": "CT CAP", "type": "DIAGNOSTIC_TEST" }, { "name": "Tumor Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2023-12-14", "completion_date": "2025-09-25", "has_results": true, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-05T10:26:17.603Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05286827" }, { "nct_id": "NCT01984892", "title": "Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Squamous Cell Carcinoma of the Head and Neck", "Squamous Cell Carcinoma of the Skin", "Sarcoma of the Skin", "Basal Cell Cancer of the Skin", "Breast Cancer" ], "interventions": [ { "name": "Poly-ICLC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nina Bhardwaj", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": null, "sex": "ALL", "summary": "14 Years and older" }, "enrollment_count": 8, "start_date": "2013-11", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2018-01-23", "last_synced_at": "2026-10-05T10:26:17.603Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01984892" } ] }